Department of Obstetrics and Gynecology and the Division of Female Pelvic Medicine and Reconstructive Surgery, Department of Obstetrics and Gynecology, Virginia Commonwealth University Health System, and the Department of Biostatistics, Virginia Commonwealth University, Richmond, Virginia.
Obstet Gynecol. 2020 Feb;135(2):352-360. doi: 10.1097/AOG.0000000000003648.
To evaluate the effects of four different surgical interventions for stress urinary incontinence (SUI) on 2-year postoperative sexual function.
This is a combined secondary analysis of SISTEr (Stress Incontinence Surgical Treatment Efficacy Trial) and TOMUS (Trial of Mid-Urethral Slings). Women in the original trials were randomized to receive surgical treatment for SUI with an autologous fascial sling or Burch colposuspension (SISTEr), or a retropubic or transobturator midurethral sling (TOMUS). Sexual function (assessed by the short version of the PISQ-12 [Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire]) was compared between groups at baseline, 12 and 24 months. Secondarily, the effects of subjective and objective surgical cure rates and the effect of concomitant surgical procedures on 24-month sexual function was explored.
Nine hundred twenty-four women were included in this study: 249 (26.9%) had an autologous fascial sling, 239 (25.9%) underwent Burch colposuspension, 216 (23.3%) had a retropubic midurethral sling placed, and 220 (23.8%) had transobturator midurethral sling placed. Baseline characteristics (including PISQ-12 scores) were similar between the four treatment arms, with notable exceptions including race-ethnicity, prolapse stage, concomitant surgery, and number of vaginal deliveries. After adjustment for differences between the groups, there was a clinically important improvement in PISQ-12 scores over the 24-month postoperative period for all treatment groups, with no significant differences attributed to the type of anti-incontinence procedure (baseline PISQ-12: 32.6, 33.1, 31.9, 31.4; 24-month PISQ-12: 37.7, 37.8, 36.9, 37.1, P<.01). There was no significant difference in mean PISQ-12 scores between 12 months and 24 months (12-month PISQ-12: 37.7, 37.8, 36.9, 37.1; 24 months as above, P=.97). Multivariable analysis showed independent associations between objective and subjective cure rates as well as concomitant procedures with a 24-month PISQ-12 score.
Women undergoing anti-incontinence surgery show overall improvement in sexual function from baseline to 24 months postoperatively, without significant differences based on surgical procedure performed. The majority of this improvement occurs in the first 12 months and is maintained over 24 months.
评估四种不同的治疗压力性尿失禁(SUI)的手术干预对术后 2 年性功能的影响。
这是 SISTEr(压力性尿失禁手术治疗效果试验)和 TOMUS(尿道中段吊带试验)的联合二次分析。原始试验中的女性被随机分配接受治疗 SUI 的手术,包括自体筋膜吊带或 Burch 悬吊带(SISTEr),或经耻骨后或经闭孔尿道中段吊带(TOMUS)。基线时、12 个月和 24 个月时,使用盆腔器官脱垂/尿失禁性功能问卷(PISQ-12)的简短版比较组间的性功能。其次,探讨主观和客观手术治愈率以及伴随手术对 24 个月性功能的影响。
本研究共纳入 924 名女性:249 名(26.9%)接受自体筋膜吊带,239 名(25.9%)接受 Burch 悬吊带,216 名(23.3%)接受耻骨后尿道中段吊带,220 名(23.8%)接受经闭孔尿道中段吊带。四组治疗组的基线特征(包括 PISQ-12 评分)相似,但种族、脱垂阶段、伴随手术和阴道分娩次数等方面存在显著差异。在调整组间差异后,所有治疗组在术后 24 个月内 PISQ-12 评分均有显著临床改善,与抗失禁手术类型无关(基线 PISQ-12:32.6、33.1、31.9、31.4;24 个月 PISQ-12:37.7、37.8、36.9、37.1,P<.01)。12 个月和 24 个月时 PISQ-12 评分的平均值无显著差异(12 个月 PISQ-12:37.7、37.8、36.9、37.1;24 个月 PISQ-12:如上所述,P=.97)。多变量分析显示,客观和主观治愈率以及伴随手术与 24 个月 PISQ-12 评分之间存在独立关联。
接受抗失禁手术的女性在术后 24 个月内性功能总体上有改善,与手术方式无关。大多数改善发生在术后 12 个月内,并持续 24 个月。